Mark L. Lupher Jr. is Director at Adverum Biotechnologies, Inc. (ADVM). They have made 1 open-market trade across 1 company since 2024, most recently 2025-12-09.
CIK 0001775323
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $176K since 2024, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ADVM | 130,000 | $567K |
Shares reported on the most recent Form 4, priced at the 2024-02-09 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ADVM | BUY | 2024-02-07 | 2024-02-09 | $1.35 | $176K | +14.1% | -2.7% | -47.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.